1/1
RISK11 signature scores for the biomarker-guided tuberculosis preventive therapy (CORTIS) randomised controlled trial
dataset
posted on 2021-01-15, 09:05 authored by Thomas ScribaThomas Scriba, Andrew Fiore-GartlandAndrew Fiore-Gartland, Adam Penn-Nicholson, Humphrey MulengaHumphrey Mulenga, Stanley KimbungStanley Kimbung, Bhavesh Borate, Simon MendelsohnSimon Mendelsohn, Katie Hadley, Chris Hikuam, Masooda Kaskar, Munyaradzi MusvosviMunyaradzi Musvosvi, Nicole Bilek, Steven Self, Tom Sumner, Richard White, Mzwandile Erasmus, Lungisa Jaxa, Rodney Raphela, Craig Innes, William Brumskine, Andriëtte Hiemstra, Stephanus T. Malherbe, Razia Hassan-Moosa, Michèle Tameris, Gerhard Walzl, Kogieleum Naidoo, Gavin Churchyard, Mark HatherillRISK11
transcriptomic signature scores for 20,207 volunteers who were screened at five
geographically diverse sites across South Africa. Signature scores were
computed from QC'ed gene expression measurements performed by
microfluidic RT-qPCR on mRNA derived from whole blood collected in
PAXgene tubes. Participants were randomised into three groups
and followed-up for 15 months to evaluate diagnostic and prognostic
performance of RISK11 and to evaluate efficacy of high-dose isoniazid
and rifapentine for prevention of incident TB.
